Finding the “Sweet Spot”: Optimizing Antipsychotic Doses After Cannabis-Induced Psychosis
Want the latest research insights delivered straight to your inbox?
Cannabis-induced psychosis (CIP) is no longer a “benign, temporary” diagnosis in real-world clinical practice. Many patients relapse, and a sizable portion eventually develop a chronic psychotic disorder trajectory.
Clinicians frequently ask:
“Should I treat CIP like first-episode psychosis?”
“What antipsychotic is best?”
“How high should I dose?”
“Can I keep doses low to minimize side effects?”
A new nationwide cohort study from Sweden provides one of the most practical answers we’ve seen so far: most oral antipsychotics appear most effective for relapse prevention when dosed in a moderate therapeutic range—not too low, and not necessarily higher.
Why this study matters?
Antipsychotics can prevent relapse after CIP, but they also carry dose-related risks:
metabolic adverse effects
sedation/cognitive dulling
hyperprolactinemia
akathisia
long-term tolerability issues leading to non-adherence
That creates a real-world dilemma:
✅ We want relapse prevention
❌ We don’t want doses so high patients stop taking them
This study specifically examined the dose–response relationship of oral antipsychotics after a first CIP diagnosis.
Study design (quick summary)
Researchers identified 1,772 individuals (ages 16–64) in Sweden with first-time CIP (ICD-10 F12.5) between 2006–2021.
Main outcome:
Hospitalization for psychotic relapse, including:
schizophrenia-spectrum disorders (F20–F29)
substance-induced psychosis (F1x.5)
Dosing was studied using Defined Daily Dose (DDD) ranges:
Low dose: <0.6 DDD/day
Medium dose: 0.6–<1.4 DDD/day
High dose: ≥1.4 DDD/day
The authors used a within-individual Cox model, meaning each patient served as their own control—reducing bias from fixed traits like genetics and baseline severity.
Key results (clinically useful takeaways)
✅ Most effective range overall: Medium dose (0.6–<1.4 DDD/day)
- Most oral antipsychotics performed best in this zone.
✅ Antipsychotics that showed benefit (with notable dose signals)
Effective options included:
Clozapine (best signal at 0.6–<1.4 DDD/day)
Olanzapine (benefit seen at ≥0.6 DDD/day)
Aripiprazole (benefit at 0.6–<1.4 DDD/day)
Risperidone (benefit at <0.6 DDD/day)
Other oral antipsychotics (benefit at 0.6–<1.4 DDD/day)
🚫 Quetiapine: No clear relapse-prevention benefit
- Quetiapine did not show significant relapse prevention in any dose range.
Translating DDD into “real doses” you actually prescribe
The authors helpfully mapped DDD categories into approximate mg/day:
| Medication | < 0.6 DDD (Low) | 0.6–<1.4 DDD (Standard) | ≥ 1.4 DDD (High) |
Olanzapine | < 6 mg/day | 6–<14 mg/day | ≥ 14 mg/day |
Aripiprazole | < 9 mg/day | 9–<21 mg/day | ≥ 21 mg/day |
Risperidone | < 3 mg/day | 3–<7 mg/day | ≥ 7 mg/day |
Quetiapine | < 240 mg/day | 240–<560 mg/day | ≥ 560 mg/day |
Clozapine | < 180 mg/day | 180–420 mg/day | ≥ 420 mg/day |
The clinical “sweet spot”: Don’t underdose CIP
One of the most useful clinical implications from this paper is:
Very low doses may not protect against relapse.
For example, aripiprazole appeared effective in the 9–<21 mg/day range, while very low dosing (<9 mg/day) may be insufficient
Practical conclusion for clinicians
For relapse prevention after CIP:
✅ Consider therapeutic, moderate dosing rather than “sub-therapeutic” dosing
✅ Most agents perform best around 0.6–<1.4 DDD/day
🚫 Quetiapine may not be the best choice if relapse prevention is your goal
Bottom line
Cannabis-induced psychosis carries a high relapse burden, and this study provides a clinically actionable dosing message:
Treat CIP relapse prevention with dosing that is “enough to work,” not just “enough to sedate.”
If you’re underdosing because you’re worried about side effects, you may unintentionally be increasing relapse risk—especially early in recovery.
Reference
Mustonen A, et al. Optimizing antipsychotic dosing for relapse prevention in cannabis-induced psychosis: A nationwide cohort study. Psychiatry Research. 2026. (article)
DEEP DIVE FOR FOR ACADEMY MEMBERS:
(1) Cannabis-Induced Psychosis:
Optimizing Antipsychotic Dosing
Unlock the full clinical detail by joining the Psychiatry Education Forum Academy:
Learning Objectives:
After this chapter, academy members will be able to:
Explain why CIP has high relapse vulnerability and why “wait-and-see” often fails.
Apply the newest real-world dose–response evidence to antipsychotic prescribing after CIP.
Identify dose ranges that are likely too low for relapse prevention (especially aripiprazole).
Recognize why quetiapine may be a weak option for CIP relapse prevention.
Build a practical relapse-prevention plan addressing cannabis exposure risk + adherence + side effects.
Optimizing Antipsychotic Dosing After Cannabis-Induced Psychosis:
(2) Cannabis Use in Adolescence & Risk of Schizophrenia
This discussion will be summarized in the following sections:
- How does Cannabis produce its effect: Role of Endocannabinoid System.
- Is there a link between cannabis use & schizophrenia?
- What are the other adverse effects of cannabis use during adolescence?
- Who is vulnerable to the harmful effects of cannabis & what determines who develops psychosis?
- Role of genetic risk factors that increase vulnerability, or resilience, to the effects of cannabis.
- Which developmental period is most sensitive to cannabinoids’ effects on memory?
- Evidence from studies of immature animals.
- Cannabis effects on neuropsychology & brain structure.
- Likely mechanism behind Cannabis effects on dopamine.
We continue to review and summarize clinically relevant research to support your daily practice.
INTERESTED IN ACCESS TO THIS & OTHER CLINICALLY RELEVANT LECTURE SERIES?
JOIN ACADEMY MEMBERSHIP:
This is a closed membership for medical professionals only.
- 400+ Clinically Relevant Chapters: Each chapter within these sections is of direct clinical relevance for your daily practice. (Table of Content)
- Journal Club: we will post the most recently published psychiatry articles relevant to your daily clinical practice. (Read Content)
- Clinical Case Discussion: Dr. Singh (Psychiatry) and Dr. Kaur (Family Medicine) discuss clinical cases to integrate the clinical cases from Psychiatry and Medicine. (Read Content)
- Monthly Insights: Gain access to our monthly sessions featuring the latest on recent publications, new medication approvals, FDA updates, and more. (Monthly Insights)
- Discussion Forum & Community: Connect with other medical professionals and discuss your difficult-to-treat clinical cases. (Academy Network)
- Goal: is to have all important clinically relevant topics in one place for ease of access.
JOIN ACADEMY MEMBERSHIP
DISCOUNTS AVAILABLE FOR: Residents & Students ONLY.
Email us your student information (program information and way to confirm your student status) to: [email protected]
© 2026 All Rights Reserved.
Responses